AMIX · XBRL financial data
Autonomix Medical financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AMIX's year ends in late March)
| In thousands of dollars | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Research and development | 2,225 | 4,725 | 7,144 |
| General and administrative | 5,249 | 6,863 | 9,890 |
| Total operating expenses | 12,030 | 11,588 | 17,034 |
| Operating income (loss) | (12,030) | (11,588) | (17,034) |
| Interest income | 127 | 354 | 319 |
| Interest expense | 79 | 176 | 0 |
| Income tax expense (benefit) | 0 | 0 | 0 |
| Net income (loss) | (15,426) | (11,410) | (16,715) |
| Earnings per share, basic‡ USD per share | (22.05) | (135.66) | (48.72) |
| Weighted average shares, basic‡ thousands of shares | 696 | 84 | 344 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-21 stock split (June 2026); filings made before it reported them unadjusted.
- † Share count changed about 4x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (AMIX's year ends in late March)
| In thousands of dollars | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|
| Cash and cash equivalents | 8,608 | 9,136 | 7,004 |
| Total current assets | 9,391 | 9,609 | 7,581 |
| Property and equipment, net | 16 | 21 | 19 |
| Total assets | 9,407 | 9,806 | 7,600 |
| Accounts payable | 492 | 676 | 700 |
| Accrued liabilities | 285 | 1,031 | 1,005 |
| Total current liabilities | 777 | 1,707 | 1,705 |
| Total liabilities | 1,779 | 1,707 | 1,705 |
| Accumulated deficit | (38,969) | (50,379) | (67,094) |
| Total stockholders' equity | 7,628 | 8,099 | 5,895 |
| Total liabilities and equity | 9,407 | 9,806 | 7,600 |
| Common shares outstanding (cover page)‡ thousands of shares | 897 | 132 | 543 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-21 stock split (June 2026); filings made before it reported them unadjusted.
- † Share count changed about 4x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (AMIX's year ends in late March)
| In thousands of dollars | Mar 31, 2024 | Mar 31, 2025 | †Mar 31, 2026 |
|---|---|---|---|
| Net income (loss) | (15,426) | (11,410) | (16,715) |
| Stock-based compensation | 618 | 1,628 | 529 |
| Depreciation and amortization | 81 | 183 | 12 |
| Net cash from operating activities | (6,648) | (8,300) | (12,282) |
| Purchases of property and equipment | 19 | 14 | 10 |
| Net cash from investing activities | (19) | (14) | (10) |
| Proceeds from issuing common stock | 2,840 | 2 | 0 |
| Net cash from financing activities | 14,410 | 8,800 | 10,160 |
| Net change in cash | 7,743 | 528 | (2,132) |
- † Share count changed about 4x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Autonomix Medical | 3,460 | 0 | (3,544) | 971,043 | 1.0 quarters | 10-QJun 30, 2026 |
| Sonoma Pharmaceuticals | 5,338 | 6,406 | (649) | 4.8M | 8.2 quarters | 10-QJun 30, 2026 |
| Odyssey Health | 122 | not reported | (160)* | 110.2M | 0.8 quarters | 10-KJul 31, 2026 |
| Family Office of America | 637 | 533 | 149* | 30.8M | — | 10-QJun 30, 2026 |
| Adm Tronics Unlimited | 223 | not reported | (33) | 67.6M | 6.8 quarters | 10-QJun 30, 2026 |
| Aethlon Medical | 4,934 | not reported | (1,897) | 711,136 | 2.6 quarters | 10-QJun 30, 2026 |
| Bone Biologics | 6,088 | not reported | (532)* | 3.4M | 9.8 quarters | 10-QSep 30, 2026 |
| SeaStar Medical Holding | 6,959 | 615 | (2,994)* | 4.4M | 2.3 quarters | 10-QJun 30, 2026 |
| ENvue Medical | 1,084 | 239 | (2,691)* | 11.1M | 0.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.